Skip to main content
TGTX
NASDAQ Life Sciences

BRIUMVI Dosing Simplified: TG Therapeutics' Phase 3 Trial Meets Primary Endpoint

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$41.08
Mkt Cap
$6.082B
52W Low
$25.28
52W High
$44.65
52W Position info
62% above low
Off High info
8.0% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

TGTX sits 62% above its 52-week low of $25.28.

Summary

TG Therapeutics announced positive topline results from its Phase 3 ENHANCE trial for BRIUMVI, its approved multiple sclerosis drug. The trial met its primary endpoint, demonstrating that a single Day 1 infusion is bioequivalent to the current two-infusion initiation regimen. This streamlined dosing simplifies treatment, potentially accelerating patient access and reducing burdens on infusion centers, which could enhance BRIUMVI's market adoption. The company plans to submit a supplemental Biologics License Application (BLA) in the second half of 2026. This follows a series of positive developments for BRIUMVI, including increased revenue guidance and completion of enrollment for a subcutaneous formulation trial.

At the time of this announcement, TGTX was trading at $41.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $25.28 to $44.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

TGTX - Latest Insights

TGTX
Nov 09, 2026, 4:33 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $63.55
Real-time Price: $63.54 info
Change: -$0.0128 (-0.02%) info
Market Cap: $9.751B info
TGTX
Nov 09, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $63.00
Real-time Price: $63.54 info
Change: +$0.5372 (+0.85%) info
Market Cap: $9.751B info
TGTX
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $58.11
Real-time Price: $63.54 info
Change: +$5.43 (+9%) info
Market Cap: $9.751B info
TGTX
Oct 23, 2026, 11:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $52.44
Real-time Price: $63.54 info
Change: +$11.10 (+21%) info
Market Cap: $9.751B info
TGTX
Aug 05, 2026, 5:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $50.48
Real-time Price: $63.54 info
Change: +$13.06 (+26%) info
Market Cap: $9.751B info